Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Toxicol In Vitro. 2017 Feb 27;41:75–82. doi: 10.1016/j.tiv.2017.02.019

Figure 4. Regulation of DME/transporter expression and CES activity in primary hepatocytes by paclitaxel.

Figure 4

Figure 4

Primary mouse hepatocytes were treated with 0.1% DMSO (vehicle) or 20 μM paclitaxel for 24 h. Gene expression (A) Cyp3a11 and Ugt1a1 (B) Mrp2 and Mdr1b were determined. All data are presented as ± S.D. and standardized for cyclophilin mRNA levels. n = 3 per group. Expression in DMSO group was set to 1, fold change after paclitaxel treatment at 24 h was compared to vehicle. (*) indicates significant difference (p < 0.05) between vehicle and paclitaxel groups; (#) indicates significant differences (p < 0.05) between paclitaxel treated samples of TLR4-wt and mutant groups. Experiments were repeated at least thrice. (C) Representative western blots from n ≥ 3 blots of hepatocytes treated with DMSO (Veh) or paclitaxel (Pac) for 24h. (D) CES activity: Whole cell extracts were prepared and CES activity was determined as described earlier. Activity data are presented as ± S.D. n = 3 per group. Experiments were repeated with three different hepatocyte preparations.